JPET Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 8, 2007; DOI: 10.1124/jpet.106.116459


0022-3565/07/3212-492-500$20.00
JPET 321:492-500, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.116459v1
321/2/492    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dell'Aica, I.
Right arrow Articles by Garbisa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dell'Aica, I.
Right arrow Articles by Garbisa, S.

INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Hyperforin Blocks Neutrophil Activation of Matrix Metalloproteinase-9, Motility and Recruitment, and Restrains Inflammation-Triggered Angiogenesis and Lung Fibrosis

Isabella Dell'Aica, Raffaele Niero, Francesco Piazza, Anna Cabrelle, Luigi Sartor, Cristiano Colalto, Enrico Brunetta, Girieca Lorusso, Roberto Benelli, Adriana Albini, Fiorella Calabrese, Carlo Agostini, and Spiridione Garbisa

Department of Experimental Biomedical Sciences, Medical School, Padova, Italy (I.D.A., L.S., C.C., S.G.); Venetian Institute of Molecular Medicine, Padova, Italy (R.N., F.P., A.C., E.B., C.A.); Department of Clinical and Experimental Medicine, Medical School, Padova, Italy (F.P., A.C., E.B., C.A.); IRCCS Multimedica, Milano, Italy (G.L., A.A.); Molecular Biology Laboratory, National Institute for Research on Cancer, Genova, Italy (R.B.); and Department of Pathology, Medical School, Padova, Italy (F.C.)

Hyperforin (Hyp), a polyphenol-derivative of St. John's wort (Hypericum perforatum), has emerged as key player not only in the antidepressant activity of the plant but also as an inhibitor of bacteria lymphocyte and tumor cell proliferation, and matrix proteinases. We tested whether as well as inhibiting leukocyte elastase (LE) activity, Hyp might be effective in containing both polymorphonuclear neutrophil (PMN) leukocyte recruitment and unfavorable eventual tissue responses. The results show that, without affecting in vitro human PMN viability and chemokine-receptor expression, Hyp (as stable dicyclohexylammonium salt) was able to inhibit in a dose-dependent manner their chemotaxis and chemoinvasion (IC50 = 1 µM for both); this effect was associated with a reduced expression of the adhesion molecule CD11b by formyl-Met-Leu-Phe-stimulated neutrophils and block of LE-triggered activation of the gelatinase matrix metalloproteinase-9. PMN-triggered angiogenesis is also blocked by both local injection and daily i.p. administration of the Hyp salt in an interleukin-8-induced murine model. Furthermore, i.p. treatment with Hyp reduces acute PMN recruitment and enhances resolution in a pulmonary bleomycin-induced inflammation model, significantly reducing consequent fibrosis. These results indicate that Hyp is a powerful anti-inflammatory compound with therapeutic potential, and they elucidate mechanistic keys.


Received October 31, 2006; accepted February 6, 2007.

Address correspondence to: Dr. Spiridione Garbisa, Department of Experimental Biomedical Sciences, viale G. Colombo 3, 35121 Padova, Italy. E-mail garbisa{at}unipd.it




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
A. Cabrelle, I. Dell'Aica, L. Melchiori, S. Carraro, E. Brunetta, R. Niero, E. Scquizzato, G. D'Intino, L. Calza, S. Garbisa, et al.
Hyperforin down-regulates effector function of activated T lymphocytes and shows efficacy against Th1-triggered CNS inflammatory-demyelinating disease
J. Leukoc. Biol., January 1, 2008; 83(1): 212 - 219.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.